RT Journal Article
SR Electronic
T1 Circulating adipokines in non-obese PCOS patients: a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.11.20210716
DO 10.1101/2020.10.11.20210716
A1 Lin, Kainan
A1 Sun, Xiaoting
A1 Wang, Xiao
A1 Wang, Hanchu
A1 Chen, Xia
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.11.20210716.abstract
AB Concentrations of circulating adipokines in non-obese polycystic ovary syndrome (PCOS) patients had been reported in many researches, however, these results were conflicting. The aim of this meta-analysis was to assess whether the levels of circulating adipokines were changed in non-obese PCOS. To identify eligible studies, literature research was performed in the database of PubMed, Embase, Web of Science without the restriction of region, publication or language. Of the total studies found, only 81 met the inclusion criteria. The meta-analysis showed that circulating levels of adiponectin [-0.95 (95% CI, −1.36 to −0.53)] decreased statistically in non-obese PCOS women. On the contrary, circulating levels of chemerin [1.13 (95% CI, 0.08 to 2.18)], leptin [0.47 (95% CI, 0.13 to 0.81)], resistin [0.45 (95% CI, 0.03 to 0.88)] and visfatin [1.38 (95% CI, 0.68 to 2.09)] increased significantly in non-obese PCOS females. Besides, there was no statistically significant change in the circulating levels of apelin [0.32 (95% CI, −1.34 to 1.99), irisin [1.01(95% CI, −0.68 to 2.70), omentin [-0.37(95% CI, −1.05 to 0.31)] and vaspin [0.09(95% CI, −0.14 to 0.32)] in non-obese PCOS patients. Scientific evidence suggested that the levels of circulating adipokines altered in non-obese PCOS patients compared with controls. Independent of the degree of obesity, the abnormal change of circulating adipokines levels might play an important role in the occurrence and development of PCOS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Wenzhou Municipal Science and Technology Bureau (Y20180271), and the Health and Family Planning Commission of Zhejiang Province (2019317125).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Wenzhou Medical UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, and code generated or used during the study appear in the submitted article